Nkarta CFO Nadir Mahmood resigns effective June 30, 2023; clinical timelines reaffirmed

Nkarta, Inc.

CFO Nadir Mahmood resigns to become CEO of a private biotech; effective June 30, 2023.
Nkarta initiates external search for new CFO.
NKX101 clinical update on track for Q2 2023; NKX019 update expected in full year 2023.
Mahmood will remain until June 30 to ensure smooth transition.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nadir Mahmood

Chief Financial and Business Officer

NKTX · Nkarta, Inc.

Effective: 2023-06-30
Filed: March 30, 2023, 7:59 PM ET

Dr. Nadir Mahmood notified Nkarta, Inc. (the “Company”) of his decision to resign as Chief Financial and Business Officer of the Company to take a position as chief executive officer of a private biotechnology company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nadir Mahmood resigned as Chief Financial and Business Officer at Nkarta, Inc..

Action: resigned
Role: Chief Financial and Business Officer

Exact text from the filing

Dr. Nadir Mahmood notified Nkarta, Inc. (the “Company”) of his decision to resign as Chief Financial and Business Officer of the Company to take a position as chief executive officer of a private biotechnology company.

View on SEC.gov

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.